

Erratum



Erratum: A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer

Yumi Kim ¹, Un-Beom Kang ², Sungsoo Kim ^{3,4}, Han-Byoel Lee ¹,
Hyeong-Gon Moon ¹, Wonshik Han ¹, Dong-Young Noh ¹

¹Department of Surgery, Seoul National University College of Medicine, Seoul, Korea

²Daegu Gyeongbuk Institute of Science & Technology, Daegu, Korea

³Interdisciplinary Graduate Program in Genetic Engineering, Seoul National University College of Natural Science, Seoul, Korea

⁴Bertis Inc. Korea, Seongnam, Korea

OPEN ACCESS

© 2020 Korean Breast Cancer Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Yumi Kim

<https://orcid.org/0000-0002-0084-337X>

Un-Beom Kang

<https://orcid.org/0000-0002-9246-4237>

Sungsoo Kim

<https://orcid.org/0000-0003-1870-3495>

Han-Byoel Lee

<https://orcid.org/0000-0003-0152-575X>

Hyeong-Gon Moon

<https://orcid.org/0000-0002-9981-0286>

Wonshik Han

<https://orcid.org/0000-0001-7310-0764>

Dong-Young Noh

<https://orcid.org/0000-0001-9418-7256>

► This corrects the article “A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer” in volume 22 on page 579.

In the article, “A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer” in Volume 22(4), page 579-586 was error in the table. In **Table 1**, the value of pNO was incorrectly listed as 29 (56.9) in ‘diagnosed as normal by biomarker’ and corrected to 39 (76.5). The authors apologize for any inconvenience that this may have caused.

The correct **Table 1** is:

Table 1. Clinicopathologic characteristics of the final confirmatory test

Characteristics	Cancer (n = 183)	Diagnosis of cancer by biomarkers (n = 132)	Diagnosed as normal by biomarkers (n = 51)	p-value
Age (yr)	51.92 ± 10.54	51.57 ± 10.77	52.82 ± 9.97	0.386
AJCC stage				0.035
0	17 (9.3)	13 (9.8)	4 (7.8)	
1	91 (49.7)	60 (45.5)	31 (60.8)	
2	73 (39.9)	57 (43.2)	16 (31.4)	
3	1 (0.5)	1 (0.7)	0 (0.0)	
LN				0.638
pN0	137 (74.9)	98 (74.2)	39 (76.5)	
pN1	45 (24.6)	33 (25.0)	12 (23.5)	
ER				0.334
Negative	54 (29.5)	40 (30.3)	14 (27.5)	
Positive	126 (68.9)	89 (67.4)	37 (72.5)	
PR				0.340
Negative	72 (39.3)	50 (37.9)	22 (43.1)	
Positive	108 (59.0)	79 (59.8)	29 (56.9)	
HER2				0.045
Negative	134 (73.2)	97 (73.5)	37 (72.5)	
Positive	12 (6.6)	7 (5.3)	5 (9.8)	
Subtypes				0.975
HR+/HER2-	111 (60.7)	80 (60.6)	31 (60.8)	
HR+/HER2+	7 (3.8)	4 (3.0)	3 (5.9)	
HR-/HER2+	5 (2.7)	3 (2.3)	2 (3.9)	
TNBC	23 (12.6)	17 (12.9)	6 (11.8)	
Ki-67 (%)				0.980
≥ 10	49 (26.8)	36 (27.3)	13 (25.5)	
< 10	129 (97.7)	92 (69.7)	37 (72.5)	
CAH1	13.05 ± 16.25	16.10 ± 18.24	5.21 ± 1.97	0.001
NCHL1	1.15 ± 0.74	1.19 ± 0.74	1.07 ± 0.74	0.972
APOC1	19.38 ± 10.27	18.60 ± 10.16	21.38 ± 10.40	0.465

Values are presented as mean ± standard deviation or number (%).

AJCC = American Joint Committee on Cancer; LN = lymph node; ER = estrogen receptor; PR = progesterone receptor; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple negative breast cancer; CAH1 = carbonic anhydrase 1; NCHL1 = neural cell adhesion molecule L1-like protein; APOC1 = apolipoprotein C-1.